Overview -- Ireland-based Jazz Pharmaceuticals plc plans to use a new, $600 million credit facility to fund the pending $650 million acquisition of EUSA Pharma Inc. -- We …
… current ratio reported, although this number inspires less confidence than that of other biotech companies such as Jazz Pharmaceuticals ( JAZZ ) , and Cell Therapeutics ( CTIC ), with current ratios of 4.2 and 3.1, respectively. Of course …
… Friday's close has a decided biotech flavor. Arena Pharmaceuticals, Synergy Pharmaceuticals (SGYPW) and Jazz Pharmaceuticals ( JAZZ ) so far have made the list of U.S. top gainers Friday. Arena Pharmaceuticals continued to ride the …
Jazz Pharmaceuticals ( JAZZ ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for as much as $700M in cash. EUSA's FDA-approved …
Jazz Pharmaceuticals ( JAZZ ): Q4 EPS of $1.17 beats by $0.08 . Revenue of $83.5M (+56.4% Y/Y) beats by $3M . Shares +2.3% AH. ( PR ) Post your comment!
… gentlemen and welcome to Jazz Pharmaceuticals Full Year and Fourth Quarter ..... questions. Welcome to the Jazz Pharmaceuticals 2011 financial results conference ..... detailed financial results for Jazz Pharmaceuticals Inc. and selected financial …
By Jessica King Holden : Jazz Pharmaceuticals ( JAZZ ) caught a lot of buzz in 2011 amid a rumored buyout by Pfizer ( PFE ), which turned out to be a confirmation of a merger …
… all have notably high P/E ratios as well. 1. Jazz Pharmaceuticals plc ( JAZZ ) Price to book: 65.04 - Price to sales: 11.54 Jazz Pharmaceuticals plc describes itself as a dynamic specialty biopharmaceutical …
Shares of Jazz Pharmaceuticals ( JAZZ ) are halted pending a news announcement. Trader chatter is centering on a potential buyout by Pfizer ( PFE ). Post your comment!
Jazz Pharmaceuticals ( JAZZ +7.9% ) double up on its AH gain yesterday following its upward revision for 2012 revenue. Adding to the momentum, analysts at Muzho upped their price target on shares to $62 from $52 based on the firm's rosy outlook. Post your comment!